Cargando…
RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum]
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113662/ https://www.ncbi.nlm.nih.gov/pubmed/35591879 http://dx.doi.org/10.2147/OTT.S371401 |
| _version_ | 1784709625925337088 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9113662 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Dove |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91136622022-05-18 RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum] Onco Targets Ther Corrigendum Dove 2022-05-13 /pmc/articles/PMC9113662/ /pubmed/35591879 http://dx.doi.org/10.2147/OTT.S371401 Text en © 2022 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| spellingShingle | Corrigendum RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum] |
| title | RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum] |
| title_full | RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum] |
| title_fullStr | RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum] |
| title_full_unstemmed | RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum] |
| title_short | RANKL/RANK Pathway Abrogates Cetuximab Sensitivity in Gastric Cancer Cells via Activation of EGFR and c-Src [Corrigendum] |
| title_sort | rankl/rank pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of egfr and c-src [corrigendum] |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113662/ https://www.ncbi.nlm.nih.gov/pubmed/35591879 http://dx.doi.org/10.2147/OTT.S371401 |